PMID- 34335798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Exploring the Regulatory Mechanism of Modified Huanglian Maidong Decoction on 
      Type 2 Diabetes Mellitus Biological Network Based on Systematic Pharmacology.
PG  - 1768720
LID - 10.1155/2021/1768720 [doi]
LID - 1768720
AB  - OBJECTIVE: To explore the mechanism of modified Huanglian Maidong decoction 
      (Maidong-Sanqi-Huanglian Compounds, MSHCs) intervention in type 2 diabetes 
      mellitus (T2DM). METHOD: This study used PubChem and SciFinder to collect the 
      molecular structure of MSHCs, used PharmMapper to predict the potential targets 
      of MSHC, and combined them with the T2DM gene to construct MSHC-T2DM 
      protein-protein interaction (PPI) network. The plugin MCODE in Cytoscape 3.7.1 
      was then used to perform cluster analysis on the MSHC-T2DM PPI network. The genes 
      and targets were input into DAVID for Gene Ontology (GO) and pathway enrichment 
      analysis. Finally, animal experiments were performed to verify the therapeutic 
      effect of MSHC on T2DM. RESULTS: Several T2DM-related targets, clusters, 
      signaling pathways, and biological processes are found. The experimental results 
      showed that compared with the blank group, the content of fasting blood glucose 
      (FBG) in the model group was higher (P < 0.01). Compared with the model group, 
      the content of FBG decreased and the insulin level increased in the MSHC 
      medium-dose (0.15 g/kg) and high-dose (0.45 g/kg) groups and metformin group 
      after 4 weeks of drug administration (P < 0.05). MSHC can also improve blood 
      liquid levels and inflammatory factor levels (P < 0.05). CONCLUSION: MSHC may 
      achieve therapeutic effects through regulating the T2DM-related targets, 
      biological processes, and pathways, such as insulin resistance, energy 
      metabolism, oxidative stress, and inflammation, found in this research.
CI  - Copyright (c) 2021 Qi He et al.
FAU - He, Qi
AU  - He Q
AD  - People's Hospital of Ningxiang City, Ningxiang City, Hunan Province, China.
FAU - Zhang, Tianqing
AU  - Zhang T
AD  - Graduate College, University of South China, Hengyang, Hunan Province, China.
FAU - Jin, Bing
AU  - Jin B
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Wu, Yonghe
AU  - Wu Y
AD  - Graduate College, University of South China, Hengyang, Hunan Province, China.
FAU - Wu, Jiamin
AU  - Wu J
AD  - Graduate College, University of South China, Hengyang, Hunan Province, China.
FAU - Gao, Pu
AU  - Gao P
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Wu, Shiwei
AU  - Wu S
AUID- ORCID: 0000-0003-4162-9537
AD  - Department of Traditional Chinese Medicine, The Eighth Affiliated Hospital, Sun 
      Yat-sen University, Shenzhen, Guangdong Province, China.
LA  - eng
PT  - Journal Article
DEP - 20210712
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8292042
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
PMCR- 2021/07/12
CRDT- 2021/08/02 05:57
PHST- 2020/07/26 00:00 [received]
PHST- 2021/06/10 00:00 [revised]
PHST- 2021/06/22 00:00 [accepted]
PHST- 2021/08/02 05:57 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
PHST- 2021/07/12 00:00 [pmc-release]
AID - 10.1155/2021/1768720 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Jul 12;2021:1768720. doi: 
      10.1155/2021/1768720. eCollection 2021.